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PURPOSE: Symptomatic vitreomacular adhesion (sVMA) is defined as visual loss secondary to foveal 25 
damage from vitreomacular traction (VMT), and includes isolated VMT, impending macular hole, and 26 
full-thickness macular hole with persisting vitreous attachment. Management options include pars 27 
plana vitrectomy, intravitreal ocriplasmin, intravitreal gas injection or observation. This synthesis of 28 
the literature aimed to assess the safety and efficacy of intravitreal gas for sVMA. 29 
METHODS: Articles describing patients with VMT or macular hole treated with intravitreal expansile 30 
gas were selected by systematic literature review using MEDLINE, EMBASE, and the Cochrane 31 
Database of Controlled Trials (CENTRAL) up to September 2016. The main outcomes at 1 month and 32 
final review were logarithm of the minimum angle of resolution (logMAR) visual acuity (VA), 33 
anatomical success (absence of both VMT and macular hole, without pars plana vitrectomy), and 34 
adverse events. The intended comparator was observation.  35 
RESULTS: Nine of 106 identified articles were eligible and none were randomized controlled trials. 36 
The mean VA of 91 eyes improved from 0.55 (6/21) to 0.48 (6/18) at 1 month and 0.35 (6/13) at final 37 
review. The mean VA at final review, prior to a vitrectomy, was 0.42 (6/16). Anatomic success was 38 
48% at 1 month and 57% at final review. The reported adverse events comprised retinal detachment 39 
in two highly myopic eyes.   40 
CONCLUSION: Intravitreal gas injection can relieve sVMA. Larger controlled studies are needed to 41 
determine safety and efficacy relative to observation, ocriplasmin, or vitrectomy.   42 
Key Words: Gas, Macula, Vitreomacular adhesion, Vitreomacular traction, Vitreous 43 
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Introduction 47 
Perifoveal vitreous separation may occur as part of normal ageing, or as part of a disease spectrum 48 
ranging from vitreomacular traction (VMT) to macular hole (MH).  Symptomatic vitreomacular 49 
adhesion (sVMA) is defined as visual loss secondary to foveal damage as a result of VMT, and 50 
includes isolated VMT, impending MH, and full thickness MH with persisting vitreous attachment 51 
(Jackson et al. 2013; Simpson et al. 2012).  52 
Treatment strategies for VMA depend on disease severity. Asymptomatic VMT can be observed, 53 
since vitreofoveal separation may occur spontaneously without sequelae. However, persisting VMT 54 
may result in foveal damage, thus prompting treatment if symptoms are significant or visual acuity 55 
(VA) is reduced (Hikichi et al. 1995; Melberg et al. 1995; Sonmez et al. 2008). For many years, pars 56 
plana vitrectomy (PPV) was the standard approach for VMT (Steel & Lotery 2013). More recently, 57 
pharmacological vitreolysis with ocriplasmin (Jetrea; Thrombogenics, Leuven, Belgium) has emerged 58 
as an alternative that may avoid the need for PPV (Benz et al. 2010; De Smet et al. 2009; Maier et al. 59 
2015; Stalmans et al. 2010; Stalmans et al. 2012; Gandorfer 2008; Jetrea Summary of Product 60 
Characteristics 2013; NICE technology appraisal guidance 2013). 61 
Another treatment modality for sVMA is pneumatic displacement with an intravitreal expansile gas 62 
bubble, potentially avoiding the need for vitrectomy or enzymatic vitreolysis.  The potential 63 
advantage of an intravitreal gas injection includes its low cost and ease of adoption. For example, 64 
the cost of ocriplasmin and vitrectomy are estimated at $3 950 (jetrea.com/JETRAOrderinginfo.pdf) 65 
and $3 147 in the USA, respectively, and £3 000 and £1 634, respectively, in the UK (Gupta et al. 66 
2008; Nicod et al. 2016). The cost of ocriplasmin is magnified by the fact that many cases fail to 67 
respond and therefore still need to progress to vitrectomy. Gases such as C3F8 and SF6 cost as little as 68 
£1 if taken from large medical gas cylinders, or typically less than £100 from single use canisters 69 
licensed for intraocular use. Intravitreal gas is easy to store and administer, and does not require the 70 
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capital costs or surgical expertise needed to undertake PPV. In addition, intravitreal gas injection 71 
may potentially be a safer procedure compared to the more invasive PPV. 72 
Given these potential advantages of intravitreal gas we undertook a review of the safety and efficacy 73 
of intravitreal gas for sVMA, to guide clinical care or future studies. Specifically, we aimed to 74 
determine the benefit of intravitreal gas in terms of releasing VMT or closing MHs, the effect on VA, 75 
and the risk in terms of intra- and postoperative complications.  76 
Materials and Methods 77 
Eligibility criteria for considering studies for this review 78 
The population was patients with sVMA, namely VMT with or without MH, to include stage 1, 2 and 79 
3 MH. The intervention was a single intravitreal expansile gas injection. The intended control was 80 
natural history. The main efficacy outcomes were VA and anatomic success, defined as an absence 81 
of VMT or MH without recourse to PPV. Both outcomes were assessed at 1 month and final follow 82 
up. Safety outcomes included all reported surgical complications or adverse events attributed to 83 
intravitreal gas. The study protocol was registered with the international prospective register of 84 
systematic reviews (2015:CRD42015017338, National Institute of Health Research Centre for 85 
Reviews and Dissemination, University of York, UK) and conducted in accordance with Preferred 86 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidance (http://www.prisma-87 
statement.org/, accessed 28 May 2015).   88 
There were no restrictions with regards to gender or ethnicity of patients or language of article. In 89 
the anticipated absence of any randomized controlled trials and to maximise safety data, 90 
prospective, retrospective, controlled and uncontrolled studies, including case reports, were eligible. 91 
Inclusion criteria were: studies of VMT or stage 1-3 MHs (Gass 1988); at least 28 days follow up; VA 92 
outcomes reported; either MH closure or VMT release rates; reporting results in adults over 18 years 93 
of age. We excluded editorials and expert opinions, and articles appearing as abstract only. Eyes with 94 
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prior treatment of VMA were excluded, including PPV, intravitreal gas, and pharmacologic 95 
vitreolysis. Eyes being treated for myopic macular hole retinal detachment were excluded. 96 
Search methods for identifying studies 97 
PubMed MEDLINE, EMBASE, and Cochrane Database of Controlled Trials (CENTRAL) searches were 98 
performed including all articles up to and including September 2016 using Boolean operators with 99 
the following keywords (and corresponding MESH headings if they were available): SF6, sulfur 100 
hexafluoride, sulphur hexafluoride, C2F6, hexafluoroethane, C3F8, octafluoropropane, 101 
perfluoropropane, gas, intravitreal, macular hole, sulphur hexafluoride, vitreomacular adhesion, and 102 
vitreomacular traction. An example search is show in Appendix 1. 103 
Study Selection 104 
Abstracts were retrieved from the search and further articles were identified in the reference lists of 105 
the retrieved articles. Two clinicians (JN and TJ) independently assessed articles for provisional 106 
eligibility based on their abstract. Full-text copies of all possibly relevant manuscripts were obtained, 107 
to determine final eligibility. Any discrepancy in eligibility was resolved by consensus following 108 
discussion. 109 
Data collection and risk of bias assessment 110 
Two reviewers (JN and TJ) extracted the relevant information into a database, including: 1) overview 111 
of the study (aim and key findings); 2) methodological details (study design, study population, 112 
inclusion criteria, exclusion criteria, intervention, comparator if available, study period); 3) VA before 113 
and after gas; 4) anatomic success after gas; 5) need for vitrectomy; 6) safety outcomes. To compare 114 
across studies, VA was converted to logarithm of the minimum angle of resolution (logMAR) units 115 
(Jackson et al. 2013). 116 
Data synthesis and analysis 117 
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Where necessary, authors were contacted to obtain unpublished raw data.  Two-sided, paired t-tests 118 
were used to compare mean VA before and after interventions. Safety was assessed by adverse 119 
events (AEs) and serious adverse events (SAEs) reported. Safety data were pooled across all studies, 120 
using individual data where available or study means otherwise. Sub-group analysis was performed 121 
for those with diagnoses of MH or VMT.  122 
Results 123 
Of 106 articles, 106 abstracts were assessed as potentially eligible, from which nine articles were 124 
deemed eligible after full text review.  A total of 91 eyes from 90 patients with sVMA were included 125 
from one non-randomized controlled study, seven uncontrolled studies and two individual case 126 
reports (Table 1) (Chan et al. 1995; Costa et al. 2001; Chen et al. 2012; Jorge et al. 2006; Mori et al. 127 
2007; Gupta & McHugh 2011; Rodrigues et al. 2013; Day et al. 2016; Yu et al. 2016). Additional, 128 
anonymous participant-level VA data were obtained from one study author as this information was 129 
not available in his report, in accordance with PRISMA guidance (Rodrigues et al. 2013). A risk of bias 130 
tool was not used as the literature search found no eligible randomised controlled trials. 131 
(Table 1 Position) 132 
There were 24 males and 59 females, with a mean age of 67.3 years (range 36 to 91, n = 85). Gender 133 
and age data were missing from one study of six eyes and the gender of a patient was not stated in 134 
one case report. There were 44 eyes (44 patients) with a baseline diagnosis of VMT, including 14 135 
with stage 1 MH. Stage 2 MH was present in 45 eyes (45 patients), and stage 3 MH in 2 eyes (2 136 
patients). One patient underwent bilateral treatment for a stage 3 MH in the right eye and a stage 2 137 
MH in the left eye. Perfluoropropane gas was used in 62 eyes, with the volume injected varying from 138 
0.2ml to 0.5ml.  Sulphur hexafluoride 0.5 ml was used in the other 29 eyes. Post-operative posturing 139 
techniques were not consistent between studies, varying from 14 days of face down posturing to no 140 
posturing. A PPV was performed in 31 of 91 eyes (34%) for varying reasons: persisting MH despite 141 
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VMT release with gas in 14 eyes (45%), persisting VMT and MH despite gas injection in eleven eyes 142 
(36%), retinal detachment in two eyes (7%), new MH following successful VMT release with gas in 143 
two eyes (7%), persisting isolated VMT in one eye (3%) and vitreous haemorrhage secondary to 144 
proliferative diabetic retinopathy in one eye (3%). 145 
At 1 month following gas injection, 44 of 91 eyes (48%) had anatomic success, defined as no VMT or 146 
MH and without recourse to PPV. At a mean final follow up period of 14.5 months (range: 1 to 48 147 
months), anatomic success was achieved in 52 eyes (57%). Twenty six eyes underwent PPV 148 
specifically for failure of gas, 14 for persisting MH, 11 for persisting combined VMT/MH, 1 for 149 
persisting isolated VMT, and all responded with anatomic success.  150 
The mean pre-intervention logMAR VA was 0.55 (n = 91; range: 0 to 2.00; Snellen equivalent 6/21). 151 
In the 62 eyes (68%) with VA documented at 1 month the mean VA improved from 0.57 logMAR by 152 
0.09 units to 0.48 logMAR (range: 0 to 2.00; 6/18; p=0.036). No eyes had undergone PPV by month 153 
1.  Mean VA at final follow up was 0.35 logMAR (n = 88; range: -0.09 to 2.00; 6/13), which was 154 
significantly better than baseline (p<0.001)(Table 2). A post hoc analysis of the final VA outcome 155 
prior to any PPV revealed a VA of 0.42 logMAR (n=78; 6/16), significantly better than baseline 156 
(p=0.001). Three patients did not have a post-gas VA documented. 157 
(Table 2 position) 158 
In the 30 eyes (33%) with a baseline diagnosis of isolated VMT, the mean VA was 0.55 logMAR 159 
(range: 0.1 to 2.00; 6/21) at baseline and remained unchanged at 0.55 (range: 0.00 to 2.00; 6/21) at 160 
month 1 (n = 22; p=0.226), before subsequently improving to 0.49 (range: 0.00 to 2.00; 6/19) at a 161 
mean follow up of 7.7 months (n=28; p = 0.096) (Figure 1). Anatomic success was achieved in 162 
fourteen eyes (47%) at month 1 and eighteen eyes (60%) at final follow up (Figure 2). Eight of 30 163 
(27%) eyes with VMT underwent PPV, all after month 1. The indication in one case was vitreous 164 
haemorrhage secondary to proliferative diabetic retinopathy in which the initial gas injection had 165 
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previously resulted in a complete posterior vitreous detachment (PVD) at month 1. In two eyes, PPV 166 
was performed for a full-thickness MH following earlier successful VMT release with gas. The other 167 
five PPVs were carried out to treat persistent VMT despite intravitreal gas injection. 168 
A stage 1 MH was present at baseline in 14 eyes. In these eyes, VA improved from 0.31 logMAR 169 
(range: 0.18 to 0.48; 6/12) to 0.23 (range: 0.00 to 1.00; 6/10) at month 1 (p=0.338), and significantly 170 
to 0.18 (range: 0.00 to 0.30; 6/9) at a mean final follow up of 12.9 months (p=0.015) (Figure 1). 171 
Anatomic success occurred in 10 of 14 eyes (71%) at 1 month post-gas, and 13 of 14 eyes (93%) at 172 
final follow up (Figure 2).  173 
The distinction between stage 1 (impending) MH and advanced VMT relies on the investigator’s 174 
judgement and did not appear to be standardised in the literature. Further, impending macular hole 175 
is often now grouped together with VMT. We therefore undertook a post hoc analysis combining 176 
VMT and stage 1 MH. In this group, VA improved from 0.45 logMAR (range: 0.00 to 2.00; 6/17) to 177 
0.43 (range: 0.00 to 2.00; 6/16) at month 1 (p=0.382), and then improved significantly, relative to 178 
baseline, to 0.39 (range: 0.00 to 2.00; 6/15) at a mean follow up of 9.4 months (p=0.019). Anatomic 179 
success occurred in 24 of 37 eyes (65%) at 1 month, and 31 of 37 eyes (84%) at final follow up. 180 
There were 45 eyes treated with intravitreal gas for a stage 2 MH, with a mean baseline VA of 0.60 181 
(range: 0.00 to 1.52; 6/24). In the 24 eyes with month 1 VA data, the mean logMAR improved to 0.54 182 
(range:  0.10 to 2.00; n = 24; 6/21). At final follow up (mean = 17.9 months), mean VA significantly 183 
improved to 0.28 logMAR (range: -0.09 to 1.00; 6/11) compared to baseline (p<0.001)(Figure 1). 184 
Anatomic success occurred in 20 of 45 eyes (44%) at month 1, and 21 of 45 eyes (47%) at final follow 185 
up (Figure 2). A PPV was undertaken in 22 eyes. In 20, the indication was failure of MH closure with 186 
gas (although 17/20 had resulted in PVD), and all PPVs were successful in closing the MH. The other 187 
2 PPVs were performed successfully to treat retinal detachment.   188 
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Two intravitreal gas procedures were performed for stage 3 MH, but neither was successful 189 
anatomically either at month 1 or by a final mean follow up of 33 months.  190 
The diameter of MH was only documented in one study of 20 stage 2 MH (Mori et al. 2007). 191 
Successful release of vitreous traction and closure of MH at both month 1 and at an average final 192 
follow up of 20 months in patients with a MH diameter <250m was 78% (7/9). Those with larger 193 
holes (>250m) had successful anatomical resolution in 27% of cases (3/11) at 1 month. All those 194 
with failed anatomical resolution at one month underwent PPV which resulted in successful MH 195 
closure.  196 
Adverse events included two retinal detachments. Both occurred in myopic eyes (-5.75D and -8.50D) 197 
with stage 2 MH. In two patients with VMT at baseline, intravitreal gas resulted in PVD at 1 month 198 
and development of a full-thickness MH which was successfully closed with PPV. One eye with an 199 
impending MH developed a full thickness MH 10 months after failed gas injection, and was 200 
successfully closed with PPV. Two eyes with stage 1 MH were diagnosed with macular pseudohole at 201 
month 13. There was one patient who was diagnosed with a retinal tear at 1 month following gas, 202 
and underwent successful laser retinopexy. No other adverse events were reported.  203 
Discussion 204 
We undertook a review to evaluate the safety and efficacy of intravitreal gas as a treatment for 205 
sVMA. We found a lack of high quality evidence. A series of uncontrolled, before/after studies found 206 
that 57% of eyes had anatomic success following intravitreal gas, defined as an absence of VMT and 207 
MH, without recourse to PPV. There was also a VA gain of 0.13 logMAR units (approximately 1 208 
Snellen line), without the need for PPV. This modest gain in VA may not fully capture the potential 209 
symptomatic benefit achieved in this patient group, given that metamorphopsia may be at least as 210 
important as VA. The good presenting VA may also impose a ceiling on any VA improvement that can 211 
be detected following gas injection. Studies of ocriplasmin and PPV for symptomatic VMA also show 212 
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modest VA gains, although the visual improvements are often better in the MH subset, compared to 213 
those with isolated VMT (Jackson et al. 2013; Stalmans et al. 2012). We also found better VA gains in 214 
those with a baseline diagnosis of MH compared to isolated VMT when treated with gas.  215 
Our literature search found one study of 20 eyes of 17 patients with VMT that underwent an 0.2ml 216 
intravitreal injection of either SF6 or C2F6 (Claus et al. 2016). This was a retrospective case series 217 
which reported an 85% (17/20) overall release of VMT, favourable visual acuity outcomes and no 218 
major safety concerns. However, we excluded this study from our analysis because there was 219 
insufficient information regarding when VMT release occurred and when post-operative visual 220 
acuities were measured (Claus et al. 2016).  221 
The management of symptomatic VMA does not currently have a gold standard, with options 222 
including observation, intravitreal gas, ocriplasmin, and PPV. Observation of VMT may lead to 223 
spontaneous separation in 17-34% of eyes, but conversely some may progress to MH, and prolonged 224 
disease may result in loss of vision (Zhang et al. 2015; Almeida et al. 2015).  225 
A combined analysis of two randomized controlled trials of ocriplasmin reported that 26.5% of eyes 226 
responded within 1 month, with no further response after this time point. Despite using a somewhat 227 
stricter definition of success (absence of both VMT and MH, not just an absence of VMT) the rate of 228 
release in our review of intravitreal gas appears higher, at 48.4% by month 1 (and 57.1% at final 229 
review). However, without direct comparison this conclusion needs to be interpreted with 230 
considerable caution, as the difference could reflect patient selection, chance, publication bias, and 231 
differences in OCT interpretation, amongst other reasons.   232 
In terms of safety, there were three cases of impending MH that progressed to full-thickness MH. In 233 
two cases, the gas injection resulted in PVD and full-thickness MH at one month, but the other 234 
occurred 10 months after gas injection so causation is unclear. A retinal tear occurred in one case, at 235 
month 1 following gas injection, which was successfully treated with laser retinopexy. Most of the 236 
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studies did not comment whether the patients were phakic or pseudophakic at baseline. Excluding 237 
cases undergoing PPV, two eyes were noted to have progression of nuclear sclerosis but neither 238 
required cataract surgery. The most clinically important AEs were two cases of retinal detachment in 239 
myopic patients (2%). This suggests that myopic eyes may be best excluded from future studies of 240 
intravitreal gas for symptomatic VMA. By extension it may also be reasonable to exclude other risk 241 
factors for retinal detachment, such as lattice degeneration or treated retinal breaks, although the 242 
risk in these patients in assumed rather than proven. The small number of eyes treated means it is 243 
not possible to quantify the overall clinical impact of retinal detachment, however, any such risks 244 
needs to be balanced against the risk of PPV or ocriplasmin. A recent literature review of PPV 245 
undertaken for VMT found a retinal detachment rate of 4.6% (Jackson et al. 2013). The retinal 246 
detachment rate in the pivotal studies of ocriplasmin was 0.4%, vs 1.6% in the placebo group 247 
(p=0.16), although several cases of retinal detachment following ocriplasmin have now been 248 
published and the true rate of RRD after ocriplasmn with longer follow up may be higher than in the 249 
phase 3 trials (Haller et al. 2015; Madi et al. 2016). 250 
The majority of adverse events associated with ocriplasmin have been considered mild, non-serious 251 
and transient such as vitreous floaters, eye pain, photopsia and reduced VA (Kaiser et al. 2015). 252 
However, concerns remain about dyschromatopsia, ERG changes and severe loss of vision, and there 253 
have been isolated case reports of ellipsoid zone changes on OCT and RPE-photoreceptor adhesion 254 
release potentially due to the enzymatic activity of the drug (Quezada Ruiz et al. 2015; Hager et al. 255 
2015; Neffendorf et al. 2016; Abraham et al. 2016; Johnson MW et al. 2015).  256 
Only one study reported MH diameter and found a higher success rate of stage 2 MH closure in 257 
small diameter holes (<250m) as opposed to those larger than 250m (78% vs 27%). This greater 258 
efficacy with smaller diameter is consistent with a sub-group analysis of the data from the pivotal 259 
ocriplasmin trial (Haller et al. 2015; Jackson et al. 2016). The influence of ERM on anatomic success is 260 
hard to determine as most studies excluded ERM, with only four cases included across all studies 261 
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(Chan et al. 1995; Day et al. 2016). Rodrigues et al reported that high reflectivity of the inner retinal 262 
surface, a possible precursor of ERM, was associated with a lower rate of VMT release (Rodrigues et 263 
al. 2013), which is also consistent with the sub-group analysis of the pivotal ocriplasmin trial (Haller 264 
et al. 2015; Jackson et al. 2016). It has been shown that phakic patients have a higher likelihood of 265 
successful sVMA release following ocriplasmin injection than pseudophakic patients (Haller et al. 266 
2015; Jackson et al. 2016; Feng et al. 2017). In our analysis, only 2 of 9 articles documented whether 267 
patients were phakic or pseudophakic at baseline and therefore due to missing data, we did not 268 
perform a subgroup analysis to further investigate whether this trend is also seen with intravitreal 269 
gas.  270 
A strength of our study is that we have pooled data in a standardised method with predefined 271 
outcome measures. However, there are several important weakness. Most importantly the number 272 
of patients is low, and only one of the studies had a control group (and in that in turn was not 273 
randomised). Accordingly, many studies may be subject to bias. Furthermore, diagnostic criteria 274 
varied across studies, as did the type and volume of gas injected and the posturing regimen. Our 275 
findings may underestimate VMT release in non-diabetic patients as our group contained 8% (7/91) 276 
diabetics, who might be expected to have firmer VMA. In addition, some studies did not report the 277 
duration of disease prior to treatment, and others had significant variability in duration (1-7 278 
months). One study was conducted in the pre-OCT era, however, it provided relatively rigorous 279 
assessment of VMA including B-scan ultrasonography (Chan et al. 1995). It is also not clear which gas 280 
offers the best efficacy.  281 
In conclusion, our synthesis of the literature suggests that there is insufficient evidence to conclude 282 
on the safety and efficacy of an intravitreal expansile gas injection for the treatment of sVMA. The 283 
limited results available do however appear to justify further research, most helpfully as a 284 
comparative study versus other management options such as observation, ocriplasmin, or 285 
vitrectomy. Diagnostic inclusion criteria can be defined using recognized photographic standards or 286 
 13 
agreed classification systems (Duker et al. 2013; Steel et al. 2016), and outcome measures could be 287 
expanded to include cataract progression, validated quality of life questionnaires and assessment of 288 
metamorphopsia (Tanner & Williamson 2000; Ugarte et al. 2013; Khadka et al. 2013; Nomoto et al. 289 
2013). An economic evaluation comparing different treatments of symptomatic VMA also appears 290 
warranted, given the potential cost advantage of intravitreal gas.  291 
 292 
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Figure Legends 440 
Figure 1: Visual acuity 441 
The graph shows the mean logarithm of the minimum angle of resolution visual acuity at baseline, 1 442 
month after intravitreal gas injection, and at final follow up prior to vitrectomy (if carried out). 443 
logMAR, logarithm of the minimum angle of resolution; MH, macular hole; VA, visual acuity; VMT, 444 
vitreomacular traction.    445 
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Figure 2: Anatomic success 460 
The chart shows anatomic success, over time, of intravitreal gas injection for each subset of 461 
symptomatic vitreomacular adhesion. Anatomic success was defined as an absence of vitreomacular 462 
traction and macular hole, without recourse to vitrectomy. MH, macular hole; VMT; vitreomacular 463 
traction. 464 
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Appendix 1: Search strategy on MEDLINE 480 
1 vitreomacular traction 481 
2 vitreomacular adhesion 482 
3 macular hole 483 
4 or/1-3 484 
5 perfluoropropane 485 
6 C3F8 486 
7 Octafluoropropane 487 
8 Sulphur hexafluoride 488 
9 Sulfur hexafluoride 489 
10 SF6 490 
11 Hexafluoroethane 491 
12 C2F6 492 
13 Gas 493 
14 or/5-13 494 
15 Intravitreal 495 
16 4 and 14 and 15 496 
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